[HTML][HTML] Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice …
C Van Poznak, MR Somerfield, RC Bast… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2015•ncbi.nlm.nih.gov
Purpose To provide recommendations on the appropriate use of breast tumor biomarker
assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A
literature search and prospectively defined study selection identified systematic reviews,
meta-analyses, randomized controlled trials (RCTs), prospective–retrospective studies, and
prospective comparative observational studies published from 2006 through September
2014. Results The literature search revealed 17 articles that met criteria for further review: 11 …
assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A
literature search and prospectively defined study selection identified systematic reviews,
meta-analyses, randomized controlled trials (RCTs), prospective–retrospective studies, and
prospective comparative observational studies published from 2006 through September
2014. Results The literature search revealed 17 articles that met criteria for further review: 11 …
Abstract
Purpose
To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer.
Methods
A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective–retrospective studies, and prospective comparative observational studies published from 2006 through September 2014.
Results
The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective–retrospective studies that evaluated the clinical utility of biomarkers.
ncbi.nlm.nih.gov